BABA
Another day, another Washington headache
Alibaba just agreed to pay $600 million to the U.S. Department of Justice to resolve allegations that its marketplaces let illegal pharmaceuticals and banned goods flow to U.S. buyers. That’s not exactly the kind of headline you want when you’re trying to convince investors your platform is a tightly run global commerce machine.
What the DOJ says happened
According to the government, merchants on Alibaba.com and AliExpress allegedly completed about 80,000 unlawful sales between January 2016 and December 2024. The shopping cart from hell reportedly included illegal pharmaceuticals, controlled substances, regulated chemicals, and even equipment used to make counterfeit pills. The DOJ also said investigators made more than 40 undercover purchases during the probe, which is a very bad look if you’re Alibaba’s compliance team.
Why the market cares
The settlement isn’t just about the check Alibaba has to write. It also reinforces a bigger investor worry: when regulators think your controls are too soft, every growth story starts to come with a side of legal risk. Alibaba says it cooperated and called the deal mutually satisfactory, but the fine print here is that the company now has to pay up, tighten controls, and keep working with investigators.
The bigger cloud over the cloud
This comes on top of other U.S. scrutiny, including Anthropic’s recent accusation that Alibaba used fraudulent accounts to harvest Claude conversations. So if you’re wondering why BABA keeps getting dragged back into the policy mud, that’s why: it’s not one messy headline, it’s a stack of them.
Big picture: investors don’t love paying for old sins, especially when the bill arrives alongside fresh scrutiny. For Alibaba, the business is still huge — but the trust gap is starting to feel like its own line item.